Eurobio Scientific SA
PAR:ALERS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.8
25.95
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Eurobio Scientific SA
Eurobio Scientific SA
PP&E Net
Eurobio Scientific SA
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eurobio Scientific SA
PAR:ALERS
|
PP&E Net
€12.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
14%
|
CAGR 10-Years
25%
|
|
|
Valneva SE
PAR:VLA
|
PP&E Net
€156.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nanobiotix SA
PAR:NANO
|
PP&E Net
€6.3m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
27%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
PP&E Net
€8.1m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
22%
|
|
|
Inventiva SA
PAR:IVA
|
PP&E Net
€8m
|
CAGR 3-Years
37%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
PP&E Net
€3.6m
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
Eurobio Scientific SA
Glance View
Eurobio-Scientific SA engages in designing, development and commercialization of tests diagnosis in the fields of transplantation, infectious diseases, autoimmunity and oncology, as well as products for research in the field of life sciences. The company is headquartered in Les Ulis, Ile-De-France. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.
See Also
What is Eurobio Scientific SA's PP&E Net?
PP&E Net
12.3m
EUR
Based on the financial report for Jun 30, 2024, Eurobio Scientific SA's PP&E Net amounts to 12.3m EUR.
What is Eurobio Scientific SA's PP&E Net growth rate?
PP&E Net CAGR 10Y
25%
Over the last year, the PP&E Net growth was 16%. The average annual PP&E Net growth rates for Eurobio Scientific SA have been 7% over the past three years , 14% over the past five years , and 25% over the past ten years .
You don't have any saved screeners yet
